BBIO vs CAT · rev $221.9M vs P/E 48, rev $20.54B
BridgeBio Pharma Inc (BBIO) versus Caterpillar Inc (CAT) — a side-by-side from cached financials, not a winner call.
BridgeBio Pharma Inc (BBIO) is a biotechnology company listed on US.
Caterpillar Inc (CAT) is a farm & heavy construction machinery company listed on NYSE. It is led by Jim Umpleby.
Latest reported BBIO revenue for 2024-12-31 was $221.9M. Net income was -$543.3M. Revenue was up 2285.3% from 2023-12-31 to 2024-12-31. BBIO currently screens at market cap $13.24B.
Latest reported CAT revenue for 2026-06-30 was $20.54B. Net income was $3.59B. Revenue was up 18.0% from 2026-03-31 to 2026-06-30. CAT currently screens at market cap $440.29B and trailing P/E 47.7.
BBIO currently screens at market cap $13.24B. CAT currently screens at market cap $440.29B and trailing P/E 47.7.
Not investment advice. Open the BBIO and CAT stock pages for the full models.
Not investment advice.